With the passage of FDAAA Title IX, FDA now has broad powers to require expanded post-market risk management for both new and previously approved prescription drugs.

 

PEGUS is already engaged supporting clients in several current REMS (Risk Evaluation and Mitigation Strategy) initiatives.  We have expertise and experience in the following key REMS-related areas:

 

• Recruiting specialized physician and patient groups for assessments

• Comprehension studies to evaluate medication guides, package inserts, boxed warnings and other written materials

• Observational / behavioral studies to evaluate real-world compliance and outcomes

• Patient Registries and AE Monitoring

• Other innovative methods to address your specific REMS needs

 

We would be happy to discuss your Risk Evaluation and Mitigation Needs. Please Contact Us for more information.

 

© PEGUS Research, Inc. 2016. Salt Lake City, Utah, United States. Tous droits réservés / All rights reserved.